GLSI

GLSI

USD

Greenwich LifeSciences Inc. Common Stock

$9.630-0.015 (-0.156%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$9.645

Máximo

$9.915

Mínimo

$9.600

Volumen

0.02M

Fundamentos de la Empresa

Capitalización de Mercado

128.7M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.08M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $8.06Actual $9.630Máximo $18.75

Noticias Relacionadas

GlobeNewswire

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Ver más
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
GlobeNewswire

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Ver más
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Ver más
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
GlobeNewswire

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,

Ver más
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.